94596-27-7

Basic information

• Product Name: Senkyunolide H
• Synonyms: Senkyunolide H;(3Z,6R,7S)-rel-3-Butylidene-4,5,6,7-tetrahydro-6,7-dihydroxy-1(3H)-isobenzofuranone
• CAS NO: 94596-27-7
• Molecular Formula: C₁₂H₁₆O₄
• Molecular Weight: 224.25300
• Product Categories: chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract
• Mol File: 94596-27-7.mol

Chemical Properties

• Boiling Point: 444.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.28
• Storage Temp.: 2-8°C
• PKA: 12.78±0.40(Predicted)
• CAS DataBase Reference: Senkyunolide H(CAS DataBase Reference)
• NIST Chemistry Reference: Senkyunolide H(94596-27-7)
• EPA Substance Registry System: Senkyunolide H(94596-27-7)

Safety Data

• Hazardous Substances Data: 94596-27-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Senkyunolide H is used as a bioactive compound for its various pharmacological activities. Its anti-atherosclerotic properties make it a potential candidate for the treatment and prevention of atherosclerosis, a disease characterized by the hardening and narrowing of arteries. Additionally, its antiproliferative effects contribute to its potential use in cancer therapy, as it can inhibit the growth and proliferation of cancer cells.
Used in Neuroprotective Applications:
Senkyunolide H is used as a neuroprotective agent for its ability to protect against MPP+-induced apoptosis in PC12 cells. This suggests its potential use in the treatment of neurodegenerative diseases, where apoptosis and oxidative stress play a significant role in the progression of the disease.

Upstream product

• 94530-85-5 senkyunolide-G 
• 81944-09-4 Z-ligustilide 

Relevant articles and documents

Metabolism of Chuanxiong Rhizoma decoction: Identification of the metabolites in WZS-miniature pig urine

Abstract Chuanxiong Rhizoma (CR), a well-known traditional Chinese medicine originated from the rhizome of Ligusticum chuanxiong Hort., was effective for treating various vascular diseases. To identify the metabolites of CR in vivo, the drug-containing urine samples of WZS-miniature pigs after orally administrated CR decoction were collected, after sequential column chromatography 17 metabolites (M1-M17) were isolated from the methanol extract of the urine samples. Their structures, including nine phthalides (M1-M9) and eight phenolic acids (M10-M17), were identified by spectroscopic means. Among them, 8 were new ones (M1-M6, M11-M12). On the basis of the structures of identified metabolites, seven original constituents, including 2 phthalides (senkyunolideI/H) and 5 phenolic acids (ferulic acid, isoferulic acid, caffeic acid, 3-hydroxycinnamoyl acid and 4-hydroxybenzonic acid) were deduced to be the major absorbed original constituents of CR in vivo. This is the first study on the metabolites of CR decoction in non-rodent animal (WZS-miniature pig), the results will give an insight into the metabolism profiles of phthalides and phenolic acids in CR decoction in vivo.